FHIT和TSLC1基因在宫颈组织中的表达及其与HPV感染的关系

Expressions of FHIT and TSLC1 genes in cervical tissues and relationship with HPV infection

目的检测宫颈组织脆性组氨酸三联体(FHIT)基因与肺癌肿瘤抑制因子1(TSLC1)基因表达,研究他们与宫颈癌发生及人类乳头瘤病毒(HPV)感染之间的关系。方法采用实时荧光聚合酶链反应(PCR)检测正常宫颈组织20例、低度鳞状上皮内病变(LSIL)20例、高度鳞状上皮内病变(HSIL)45例及宫颈癌患者标本33例FHIT基因及TSLC1基因表达,同时检测这些标本中高危型HPV感染情况。结果正常宫颈组织、LSIL、HSIL和宫颈癌组织中HPV的感染率、FHIT基因表达率及TSLC1基因表达率分别为0%、30%、71%和100%,100%、80%、36%和18%以及100%、75%、33%和24%。3项指标在不同宫颈组织之间差异有统计学意义(P<0.01)。所有FHIT基因与TSLC1基因表达缺失的患者均存在高危型HPV感染。受试者工作特征(ROC)曲线分析表明检测FHIT与TSLC1基因表达缺失对宫颈癌及HSIL具有诊断价值。结论 FHIT基因与TSLC1基因在HPV感染之后、宫颈癌发生过程的早期阶段就可能发生表达缺失。对高危型HPV感染者进行FHIT与TSLC1基因表达检测,有可能成为宫颈癌早期诊断的重要参考依据。

Objective To study the expressions of fragile histidine triad（FHIT） gene and tumor suppressor in lung cancer 1（TSLC1） gene in cervical tissues and the relationship with the occurrence of cervical cancer and human papillomavirus（HPV） infection.Methods The FHIT and TSLC1 gene expressions and high-risk HPV were detected in normal cervical tissues（20 cases）,low-grade squamous intraepithelial lesion（LSIL） tissues（20 cases）,high-grade squamous intraepithelial lesion（HSIL） tissues（45 cases） and cervical cancer tissues（33 cases） by real-time polymerase chain reaction（PCR）.Results The rates of HPV infection and FHIT and TSLC1 expressions in normal cervical tissues,LSIL tissues,HSIL tissues and cervical cancer tissues were 0%,30%,71% and 100%;100%,80%,36% and 18%;100%,75%,33% and 24%,respectively.Each of the 3 rates was significantly different between the different cervical tissues（P0.01）.High-risk HPV infection was detected in all the patients with FHIT and TSLC1 gene expression loss.The receiver operating characteristic（ROC） curve analysis showed that detection of FHIT and TSLC1 gene expression loss had diagnostic values for cervical cancer and HSIL.Conclusions The losses of FHIT and TSLC1 gene expressions may occur at the early stage of cervical cancer after HPV infection.The detections of FHIT and TSLC1 gene expressions in patients with high-risk HPV infection may provide important markers for cervical cancer diagnosis.